IMMVF Stock UPDATES Immuno Vaccine Inc (IMMVF) 0.7869 09/10/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 10, 2014 at 1:22 PM

Immuno Vaccine Inc (IMMVF) 0.7869 $IMMVF

Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg

IIROC Trade Resumption - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 1:20PM CDT
Trading resumes in:

IIROC Trade Halt - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 7:08AM CDT
The following issues have been halted by IIROC:

Ebola Vaccine Using Immunovaccine's DepoVax Proves Highly Efficacious in Non-Human Primate Study
Marketwire - Mon Aug 25, 9:31AM CDT
Immunovaccine Inc. ("Immunovaccine"

(TSX VENTURE: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax(TM) technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In a preliminary study using cynomolgus monkeys, which are particularly sensitive to the Ebola virus, all vaccinated subjects survived exposure to a lethal dose of the wild type Zaire strain of the virus. All unvaccinated control animals succumbed to the disease.

Immunovaccine Announces Financial Results for Quarter Ended June 30, 2014
Marketwire - Fri Aug 15, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV"

(TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended June 30, 2014.

Immunovaccine to Present at Ninth Annual Immunotherapies and Vaccines Summit (ImVacS) Conference
Marketwire - Tue Aug 12, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV"

(TSX VENTURE: IMV), a clinical stage vaccine company, announced today that Marc Mansour, Ph.D., the Company's chief executive officer, will make a presentation at the Ninth Annual Immunotherapies and Vaccines Summit (ImVacS). In addition to his presentation, Dr. Mansour will also serve as chairperson of the conference's "Clinical Updates of Combination Immunotherapies" session. The conference will take place on August 11-14, 2014 at the Marriott Long Wharf Hotel in Boston, MA.

Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies
Marketwire - Tue Apr 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine"

(TSX VENTURE: IMV) and Pfenex Inc. ("Pfenex"

today announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses.

Immunovaccine Announces 2013 Year-End Results
Marketwire - Mon Mar 17, 7:06AM CDT
Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013.

MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.

Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Immunovaccine Inc names Dr Llew Keltner to board
M2 - Tue Jan 21, 4:13AM CST
Immunotherapy company Immunovaccine Inc (TSX VENTURE:IMV) reported on Monday the addition of Dr Llew Keltner, MD, PhD to its board of directors with immediate effect.

Llew Keltner, US Biotech Industry Adviser, Joins Board of Immunovaccine
Marketwire - Mon Jan 20, 7:08AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company"

(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...